Based on the theory that tumour cell survival during DNA damage largely depends on efficient cell cycle checkpoints, we further demonstrated that the combination of SHCBP1 inhibition and low-dose DNA-damaging drugs had synergistic effects on tumouor therapy. This evidence concerns the gene SHCBP1 and neoplasm.